ASX Share rice
Sat 15 May 2021 - 01:53:am (Sydney)

HYD Share Price

HYDRIX LIMITEDHYDTechnology Hardware & Equipment

HYD Company Information

Name:

Hydrix Limited

Sector:

Technology

Industry:

Scientific & Technical Instruments

GIC Industry:

Electronic Equipment, Instruments & Components

GIC Sub Industry:

Electronic Equipment & Instruments

Address:

30-32 Compark Circuit Mulgrave VIC Australia 3170

Phone:

61 3 9550 8100

Full Time Employees:

60

Exec. Chairman:

Mr. Gavin Coote

Exec. VP of Corp. Devel.:

Mr. Peter R. Lewis A.M.

Financial Controller:

Mr. Mark Langham

Corp. Counsel & Company Sec.:

Ms. Alyn Tai L.L.B., LLB (Hons)

Marketing Mang.:

Mr. Alan Morris

Chief People Officer:

Ms. Mandy Kelly

Chief Research Officer:

Dr. John Bumgarner

GM of Hydrix Medical & Member of Medical Advisory Board:

Mr. Paul Kelly

Specialist Biosciences Adviser & Member of Advisory Board:

Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D.

Company Overview:

Hydrix Limited provides product design, engineering, and regulatory services in Australia and internationally. It offers a range of services, including software, electronics, and mechanical design; industrial, user experience, and human factors engineering; and regulatory, clinical, and reimbursement consulting, as well as quality systems. The company also engages in the product distribution that focuses on the cardiovascular technologies with the potential to improve the quality of patient life and mobility; and early stage venture investment. It serves medical, consumer, industrial, mining, defense, and rail industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia.

HYD Share Price Information

Shares Issued:

162.82M

Market Capitalisation:

$28.49M

Revenue (TTM):

$12.79M

Revenue Per Share (TTM):

$0.13

Earnings per Share:

$-0.007

Profit Margin:

-0.4978

Operating Margin (TTM):

$-0.21

Return On Assets (TTM):

$-0.09

Return On Equity (TTM):

$-1.03

Quarterly Revenue Growth (YOY):

-0.378

Gross Profit(TTM):

$14.31M

Diluted Earnings Per Share (TTM):

$-0.063

HYD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-1,012,510

Change To Liabilities:

$-108,719

Total Cashflow From Investing Activities:

$-1,067,482

Net Borrowings:

$1.60M

Net Income:

$-3,219,461

Total Cash From Operating Activities:

$-1,316,565

Depreciation:

$635.53K

Other Cashflow From Investing Activities:

$-1,024,870

Change To Account Receivables:

$598.78K

Sale Purchase Of Stock:

$2.57M

Capital Expenditures:

$42.61K

HYD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-2,872,730

Net Income:

$-3,219,460

Gross Profit:

$13.63M

Operating Income:

$-2,776,020

Other Operating Expenses:

$2.22M

Interest Expense:

$890.02K

Income Tax Expense:

$346.73K

Total Revenue:

$15.21M

Cost Of Revenue:

$1.58M

HYD Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$7.88M

Total Liabilities:

$16.73M

Total Stockholder Equity:

$2.30M

Other Current Liabilities:

$2.23M

Total Assets:

$19.02M

Common Stock:

$82.51M

Other Current Assets:

$681.83K

Retained Earnings:

$-82,025,843

Other Liabilities:

$2.96M

Good Will:

$1.27M

Other Assets:

$445.75K

Cash:

$1.69M

Total Current Liabilities:

$4.63M

Short-Term Debt:

$276.66K

Property - Plant & Equipment:

$2.87M

Net Tangible Assets:

$-5,579,887

Long-Term Investments:

$2.66M

Total Current Assets:

$5.60M

Long-Term Debt:

$5.74M

Net Receivables:

$3.77M

Short-Term Investments:

$13.42M

Accounts Payable:

$684.37K

Non Currrent Assets (Other):

$20.77K

Short-Term Investments:

$13.42

Non Current Liabilities (Other):

$2.52M

Non Current Liabilities Total:

$12.10M

HYD Share Price History

HYD News

08 Mar, 2021
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
15 Jan, 2021
NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the closing of a previously announced private placement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock. Each share of common stock and corresponding warrant is being sold at an aggregate purchase price of $1.00 for gross proceeds of $12,500,000. The exercise price of each warrant is $1.75 per share and are exercisable for a period of five years from the date of issuance.
12 Jan, 2021
NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has entered into a definitive purchase agreement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock to certain investors in a private placement. Each share of common stock and corresponding warrant is being sold at an aggregate purchase price of $1.00 for anticipated gross proceeds of $12,500,000. The proposed offering is anticipated to close on or about January 14, 2021, subject to the satisfaction of customary closing conditions. Proceeds from the proposed offering are expected to be used for general corporate and working capital purposes. Kestrel Merchant Partners LLC is acting as the exclusive sponsor and The Benchmark Company, LLC is acting as the sole placement agent for the proposed offering.
07 Jan, 2021
NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Ronald McClurg, an experienced senior financial industry executive, as Chief Financial Officer of NeuroOne Medical Technologies Corporation. Mr. McClurg has over 30 years of financial leadership experience with both public and privately held companies. He has held the role of CFO for a number of public companies including Orthomet, Inc., Video Sentry Corporation, and Insignia Systems, Inc. He also held the role of CFO at Incisive Surgical, a privately held medical device company. He began his career in public accounting with Ernst and Young, where he earned his CPA certificate.
03 Dec, 2020
NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota.